FGL2

From Wikipedia, the free encyclopedia
FGL2
Identifiers
AliasesFGL2, T49, pT49, fibrinogen like 2
External IDsOMIM: 605351 MGI: 103266 HomoloGene: 4864 GeneCards: FGL2
Orthologs
SpeciesHumanMouse
Entrez

10875

14190

Ensembl

ENSG00000127951

ENSMUSG00000039899

UniProt

Q14314

P12804

RefSeq (mRNA)

NM_006682

NM_008013

RefSeq (protein)

NP_006673

NP_032039

Location (UCSC)Chr 7: 77.19 – 77.2 MbChr 5: 21.37 – 21.38 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Fibrinogen-like protein 2, also known as FGL2, is a protein which in humans is encoded by the FGL2 gene.[5][6]

Structure[]

FGL2 is a 439 amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen. The carboxyl-terminus of the encoded protein consists of the fibrinogen-related domains (FRED). The encoded protein forms a tetrameric complex which is stabilized by interchain disulfide bonds.[5]

Function[]

This protein may play a role in physiologic functions at mucosal sites.

FGL2 is a protein that exhibits pleiotropic effects within the body and is an important immune regulator of both innate and adaptive responses.[7] The protein exists as both a Type II transmembrane protein (with the carboxy terminus on the extracellular side of the plasma membrane) found on the surface of macrophages and endothelial cells and can be constitutively secreted by both CD4+ and CD8+ T cells.[7]

Variants[]

Membrane bound[]

Membrane bound FGL2 (mFGL2) exhibits a prothrombinase activity, resulting in fibrin deposition, vascular thrombosis and tissue inflammation within an affected tissue, largely contributing to the innate arm of immunity.[8] Through mFGL2’s actions of promoting vascular thrombosis and tissue inflammation, it has been implicated in the pathogenesis of viral-induced fulminant hepatitis in acute hepatitis B infections.[9] Hepatocellular necrosis ensues rapidly, due to the HBV nucleocapsid protein’s ability to markedly upregulate expression of the mFGL2 prothrombinase, leading to fibrin deposition within the vasculature networks that supply blood to the liver.[9]

Secreted[]

In addition to its constitutive secretion by CD4+ and CD8+ T cells, the secreted form of FGL2 (sFGL2) can be inducibly secreted by Foxp3+ CD4+ CD25+ T regulatory cells (Tregs). Such Treg cells play a vital role in dampening the immune response after the clearance of an infection to prevent sterile inflammation. These cells also play a fundamental role in maintaining self tolerance by suppressing the activation and expansion of self-reactive lymphocytes that may instigate autoimmunity.[citation needed]9 Through their roles in immune homeostasis, it has been shown that depletion of the Treg cell population in murine models for disease lead to enhanced immune responses to a variety of infectious agents including hepatitis C virus (HCV).[citation needed]10 Additionally, patients with a chronic HCV infection were shown to have higher counts of Treg cells in peripheral blood when compared with successfully treated or healthy controls.[citation needed]11

Secreted FGL2 (sFGL2) plays a role as a negative regulator of the Immune response. sFGL2 inhibits the adaptive immune response. Knockout mice for FGL2 have T cells that are hyperproliferative.[10] sFGL2 is capable of inhibiting the proliferation of T cells stimulated by alloantigens and this inhibition is alleviated by the addition of a monoclonal antibody against sFGL2’s fibrinogen-like domain (FRED).[citation needed]12 When the supernatants of these T cell cultures are analyzed, they showed a predominant Th2 type polarization with upregulated levels of expression of interleukin-4 (IL-4) and Interleukin-10 (IL-10).[citation needed]12 There are also downregulated levels of Th1-type cytokines such as interleukin-2 (IL-2) and interferon γ (IFN-γ).[10] This shows that sFGL2 largely inhibits the Th1 type response needed to activate cytotoxic lymphocytes to clear HCV infections. Additionally, sFGL2 can inhibit the maturation of immature dendritic cells (DCs) by preventing NF-κB translocation to the nucleus and subsequent expression of the co-stimulatory molecule CD80 and major histocompatibility complex II (MHC II).[10] Therefore, sFGL2 may contribute to the negative regulatory activity exhibited by Treg cells.

sFGL2 works to repress immune response through its FRED Domain. The immunosuppressive activity of sFGL2 has been localized to the C-terminal region containing the FRED domain. sFGL2’s FRED domain shares significant homology to the fibrinogen related domains of potent immunoregulatory molecules like and tenascin.[citation needed]12 This works to repress immune responses by binding to the inhibitory FC receptor, FCγRIIB. Furthermore, HCV’s core protein has been found to increase the levels of expression of sFGL2 and cause virus-specific CD4+ T lymphocytes to skew largely toward a Th2 lineage, allowing for the establishment of a chronic infection.[citation needed]13

Clinical significance[]

Human Fibrinogen-like protein 2 may be useful as a biomarker for responsiveness to antiviral therapy.[11]

References[]

  1. ^ Jump up to: a b c GRCh38: Ensembl release 89: ENSG00000127951 - Ensembl, May 2017
  2. ^ Jump up to: a b c GRCm38: Ensembl release 89: ENSMUSG00000039899 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Jump up to: a b "Entrez Gene: FGL2 fibrinogen-like 2".
  6. ^ Rüegg C, Pytela R (July 1995). "Sequence of a human transcript expressed in T-lymphocytes and encoding a fibrinogen-like protein". Gene. 160 (2): 257–62. doi:10.1016/0378-1119(95)00240-7. PMID 7642106.
  7. ^ Jump up to: a b Marazzi S, Blum S, Hartmann R, Gundersen D, Schreyer M, Argraves S, von Fliedner V, Pytela R, Rüegg C (July 1998). "Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes". J. Immunol. 161 (1): 138–47. PMID 9647217.
  8. ^ Ghanekar A, Mendicino M, Liu H, He W, Liu M, Zhong R, Phillips MJ, Levy GA, Grant DR (May 2004). "Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection". J. Immunol. 172 (9): 5693–701. doi:10.4049/jimmunol.172.9.5693. PMID 15100314.
  9. ^ Jump up to: a b Shalev I, Wong KM, Foerster K, Zhu Y, Chan C, Maknojia A, Zhang J, Ma XZ, Yang XC, Gao JF, Liu H, Selzner N, Clark DA, Adeyi O, Phillips MJ, Gorczynski RR, Grant D, McGilvray I, Levy G (February 2009). "The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis". Hepatology. 49 (2): 387–97. doi:10.1002/hep.22684. PMID 19085958. S2CID 205867959.
  10. ^ Jump up to: a b c Hancock WW, Szaba FM, Berggren KN, Parent MA, Mullarky IK, Pearl J, Cooper AM, Ely KH, Woodland DL, Kim IJ, Blackman MA, Johnson LL, Smiley ST (March 2004). "Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFN gamma-inducible fibrinogen-like protein 2". Proc. Natl. Acad. Sci. U.S.A. 101 (9): 3005–10. Bibcode:2004PNAS..101.3005H. doi:10.1073/pnas.0308369101. PMC 365735. PMID 14976252.
  11. ^ "FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy". ClinicalTrials.gov. Retrieved 2009-03-28.

[12] Chan CW et al. "Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells." J Immunol. 2003 Apr 15;170(8):4036-44.

Further reading[]


Retrieved from ""